FMC Corp. directors allegedly misled investors about post-pandemic inventory levels and generic competition issues weighing on demand, causing the agricultural-sciences company to face costs from a potential securities class action just as some executives netted millions from insider trading, a shareholder derivative action says.
FMC distributors and retailers, through which it primarily sold its products, amassed excess inventory to head off supply chain fears during the pandemic, said Greg Menke in his complaint filed in the US District Court for the Eastern District of Pennsylvania on Thursday. But demand began to decline in 2022 and 2023, he said, and FMC’s ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.